731
Views
8
CrossRef citations to date
0
Altmetric
Editorials

The clinical potential for koff-rate measurement in adoptive immunotherapy

, &
Pages 1151-1153 | Published online: 10 Jan 2014
 

Acknowledgements

The authors wish to thank R Knall for providing experimental data on OT-1 T cells, P Paszkiewicz and C Stemberger for carefully reading the manuscript.

Financial & competing interests disclosure

The authors were supported by SFB TR36 (TP-B10/13). Streptamer technology is covered by US Patent 4,776,562 (patent holder Dirk H. Busch and Hermann Wagner). Streptamer products are commercialized by IBA GmbH (Göttingen) and Stage Cell Therapeutics (Göttingen). The authors have no other relevant affiliations or other financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.